Should left ventricular assist device should be standard of care for patients with refractory heart failure who are not transplantation candidates?: Left ventricular assist devices should be considered standard of care for patients with refractory heart failure who are not transplantation candidates

Circulation

Volumn 126, Issue 25, 2012, Pages 3081-3086

  Mehra, Mandeep R ^a   Domanski, Michael J ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INOTROPIC AGENT;

ADL DISABILITY; ARTICLE; ASSISTED CIRCULATION; CLASSIFICATION ALGORITHM; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; DEVICE THERAPY; HEALTH CARE COST; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART TRANSPLANTATION; HUMAN; INTERMETHOD COMPARISON; INTRAAORTIC BALLOON PUMP; LEFT VENTRICULAR ASSIST DEVICE; LUNG CONGESTION; MEDICAL TECHNOLOGY; PATIENT CARE; PATIENT SELECTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STEM CELL TRANSPLANTATION; SURVIVAL; TREATMENT OUTCOME;

HEART FAILURE; HEART TRANSPLANTATION; HEART-ASSIST DEVICES; HUMANS; PATIENT SELECTION; STANDARD OF CARE;

EID: 84871267399     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.079301     Document Type: Article

References (27)

1. Frazier OH. Prologue: ventricular assist devices and total artificial hearts: a historical perspective. Cardiol Clin. 2003;21:1-13.
2. Egnaczyk G, Milano CA, Rogers JG. Clinical trials in mechanical circulatory support. Heart Fail Clin. 2011;7:457-466.
3. Mehra MR. Ventricular assist devices: destination therapy or just another stop on the road? Curr Heart Fail Rep. 2004;1:36-40.
4. Slaughter MS, Pagani FD, Rogers JG, Miller LW, Sun B, Russell SD, Starling RC, Chen L, Boyle AJ, Chillcott S, Adamson RM, Blood MS, Camacho MT, Idrissi KA, Petty M, Sobieski M, Wright S, Myers TJ, Farrar DJ; HeartMate II Clinical Investigators. Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. J Heart Lung Transplant. 2010;29:S1-S39.
5. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dem-bitsky W, Long JW, Ascheim DD, Tierney AR, Levitan RG, Watson JT, Meier P, Ronan NS, Shapiro PA, Lazar RM, Miller LW, Gupta L, Frazier OH, Desvigne-Nickens P, Oz MC, Poirier VL; Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001;345:1435-1443.
6. Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, Sun B, Tatooles AJ, Delgado RM 3rd, Long JW, Wozniak TC, Ghumman W, Farrar DJ, Frazier OH; HeartMate II Investigators. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361:2241-2251.
7. Rogers JG, Butler J, Lansman SL, Gass A, Portner PM, Pasque MK, Pierson RN 3rd; INTrEPID Investigators. Chronic mechanical circulatory support for inotrope-dependent heart failure patients who are not transplant candidates: results of the INTrEPID Trial. J Am Coll Cardiol. 2007;50:741-747.
8. Kirklin JK, Naftel DC, Kormos RL, Stevenson LW, Pagani FD, Miller MA, Ulisney KL, Baldwin JT, Young JB. Second INTERMACS annual report: more than 1, 000 primary left ventricular assist device implants. J Heart Lung Transplant. 2010;29:1-10.
9. Kirklin JK, Naftel DC, Kormos RL, Stevenson LW, Pagani FD, Miller MA, Ulisney KL, Baldwin JT, Young JB. Third INTERMACS annual report: the evolution of destination therapy in the United States. J Heart Lung Transplant. 2011;30:115-123.
10. Kirklin JK, Naftel DC, Kormos RL, Stevenson LW, Pagani FD, Miller MA, Baldwin JT, Young JB. The Fourth INTERMACS annual report: 4, 000 implants and counting. J Heart Lung Transplant. 2012;31:117-126.
11. Park SJ, Milano CA, Tatooles AJ, Rogers JG, Adamson RM, Steidley DE, Ewald GA, Sundareswaran KS, Farrar DJ, Slaughter MS. Outcomes in Advanced Heart Failure Patients with Left Ventricular Assist Devices for Destination Therapy. Circ Heart Fail. 2012;5:241-248.
12. Hasin T, Topilsky Y, Schirger JA, Li Z, Zhao Y, Boilson BA, Clavell AL, Rodeheffer RJ, Frantz RP, Edwards BS, Pereira NL, Joyce L, Daly R, Park SJ, Kushwaha SS. Changes in renal function after implantation of continuous-flow left ventricular assist devices. J Am Coll Cardiol. 2012; 59:26-36.
13. Boyle AJ, Ascheim DD, Russo MJ, Kormos RL, John R, Naka Y, Gelijns AC, Hong KN, Teuteberg JJ. Clinical outcomes for continuous-flow left ventricular assist device patients stratified by pre-operative INTERMACS classification. J Heart Lung Transplant. 2011;30:402-407.
14. Baldwin JT, Mann DL. NHLBI's program for VAD therapy for moderately advanced heart failure: the REVIVE-IT pilot trial. J Card Fail. 2010;16:855-858.
15. Pamboukian SV, Tallaj JA, Brown RN, Holman WL, Blood M, George JF, Costanzo MR, Cadeiras M, Smallfield MC, McGiffin DC, Kirklin JK. Improvement in 2-year survival for ventricular assist device patients after implementation of an intensive surveillance protocol. J Heart Lung Transplant. 2011;30:879-887.
16. Mehra MR, Griffith BG. Assisted circulation in the treatment of heart failure. In: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 9th ed. Philadelphia, PA: Elsevier Saunders; 2011:617-626.
17. Wang Y, Simon MA, Bonde P, Harris BU, Teuteberg JJ, Kormos RL, Antaki JF. Decision tree for adjuvant right ventricular support in patients receiving a left ventricular assist device. J Heart Lung Transplant. 2012; 31:140-149.
18. Baumwol J, Macdonald PS, Keogh AM, Kotlyar E, Spratt P, Jansz P, Hayward CS. Right heart failure and "failure to thrive" after left ventricular assist device: clinical predictors and outcomes. J Heart Lung Transplant. 2011;30:888-895.
19. Cleveland JC Jr, Naftel DC, Reece TB, Murray M, Antaki J, Pagani FD, Kirklin JK. Survival after biventricular assist device implantation: an analysis of the Interagency Registry for Mechanically Assisted Circulatory Support database. J Heart Lung Transplant. 2011;30:862-869.
20. Rogers JG, Bostic RR, Tong KB, Adamson R, Russo M, Slaughter MS. Cost-effectiveness analysis of continuous-flow left ventricular assist devices as destination therapy. Circ Heart Fail. 2012;5:10-16.
21. Winkelmayer WC, Weinstein MC, Mittleman MA, Glynn RJ, Pliskin JS. Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making. 2002;22:417-430.
22. Frazier OH, Khalil HA, Benkowski RJ, Cohn WE. Optimization of axial-pump pressure sensitivity for a continuous-flow total artificial heart. J Heart Lung Transplant. 2010;29:687-691.
23. Petrucci RJ, Rogers JG, Blue L, Gallagher C, Russell SD, Dordunoo D, Jaski BE, Chillcott S, Sun B, Yanssens TL, Tatooles A, Koundakjian L, Farrar DJ, Slaughter MS. Neurocognitive function in destination therapy patients receiving continuous-flow vs pulsatile-flow left ventricular assist device support. J Heart Lung Transplant. 2012;31:27-36.
24. Norton C, Georgiopoulou VV, Kalogeropoulos AP, Butler J. Epidemiology and cost of advanced heart failure. Prog Cardiovasc Dis. 2011;54: 78-85.
25. Stehlik J, Edwards LB, Kucheryavaya AY, Benden C, Christie JD, Dobbels F, Kirk R, Rahmel AO, Hertz MI. The Registry of the International Society for Heart and Lung Transplantation: twenty-eighth adult heart transplant report\2011. J Heart Lung Transplant. 2011;30: 1078-1094.
26. Pierson RN 3rd, Dorling A, Ayares D, Rees MA, Seebach JD, Fishman JA, Hering BJ, Cooper DK. Current status of xenotransplantation and prospects for clinical application. Xenotransplantation. 2009;16: 263-280.
27. Bolli R, Chugh AR, D'Amario D, Loughran JH, Stoddard MF, Ikram S, Beache GM, Wagner SG, Leri A, Hosoda T, Sanada F, Elmore JB, Goichberg P, Cappetta D, Solankhi NK, Fahsah I, Rokosh DG, Slaughter MS, Kajstura J, Anversa P. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet. 2011;378:1847-1857.